Dose Escalation Study to Assess Safety, Tolerability, and Efficacy of Budiodarone Treatment With Non-permanent Atrial Fibrillation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT07792239

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Xyra, LLC (from the registry)
Registry
  • NCT NCT07792239
  • EU CT 2025-523860-19-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Poland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07792239. Allocation not applicable; no masking; primary purpose treatment. Start 2026-08-06 (actual); primary completion 2027-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dose Escalation Study to Assess Safety, Tolerability, and Efficacy of Budiodarone Treatment With Non-permanent Atrial Fibrillation
Acronym
Harbor-AF
Condition
Atrial Fibrillation (AF)
Condition
Paroxysmal AF
Intervention (Drug)
Budiodarone 200 mg BID
Intervention (Drug)
Budiodarone 400 mg BID
Intervention (Drug)
Budiodarone 600 mg BID
Intervention (Drug)
Budiodarone 800 mg BID
Lead sponsor
Xyra, LLC (class: industry)
Collaborator
Amarex Clinical Research (class: other)

Record details

Record id
cardio:ct-nct07792239
Content hash
a50060284e87608c421af22e2fd9656407f18bdb137046f4e70b121ccf62a705